A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Innovent Biologics, Inc.
Related studies linked through entity extraction aliases.
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
- Status
- UNKNOWN
- Phase
- N/A
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2